Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-LILRB4/ILT3/CD85k Antibody
Copy Product Info
🥰Excellent
Catalog No. T9901A-1430
Anti-LILRB4/ILT3/CD85k Antibody is a potent monoclonal antibody targeting the inhibitory receptor LILRB4, acting by blocking the binding of LILRB4 to its ligands such as APOE. The compound is an essential tool for investigating myeloid immune checkpoints, immune escape in acute myeloid leukemia (AML), and mechanisms of immune tolerance induction, aiming to restore the anti-tumor activity of effector T cells by lifting LILRB4-mediated signaling inhibition.
Anti-LILRB4/ILT3/CD85k Antibody
Anti-LILRB4/ILT3/CD85k Antibody
Copy Product Info🥰Excellent
Catalog No. T9901A-1430
Anti-LILRB4/ILT3/CD85k Antibody is a potent monoclonal antibody targeting the inhibitory receptor LILRB4, acting by blocking the binding of LILRB4 to its ligands such as APOE. The compound is an essential tool for investigating myeloid immune checkpoints, immune escape in acute myeloid leukemia (AML), and mechanisms of immune tolerance induction, aiming to restore the anti-tumor activity of effector T cells by lifting LILRB4-mediated signaling inhibition.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Add to Quotation
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Anti-LILRB4/ILT3/CD85k Antibody is a potent monoclonal antibody targeting the inhibitory receptor LILRB4, acting by blocking the binding of LILRB4 to its ligands such as APOE. The compound is an essential tool for investigating myeloid immune checkpoints, immune escape in acute myeloid leukemia (AML), and mechanisms of immune tolerance induction, aiming to restore the anti-tumor activity of effector T cells by lifting LILRB4-mediated signaling inhibition. |
| In vitro | In human monocytic AML cell lines (e.g., MV4-11), Anti-LILRB4/ILT3/CD85k Antibody (h12F6) blocked APOE binding to LILRB4 and inhibited SHP-1 recruitment, restoring T cell cytotoxicity [1]. |
| In vivo | In NSG mouse models with human AML xenografts, systemic administration of Anti-LILRB4/ILT3/CD85k Antibody (h12F6) reduced leukemia cell infiltration into the liver and brain and prolonged survival [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | LILRB4/IL-T3/CD85k |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Anti-LILRB4/ILT3/CD85k Antibody | purchase Anti-LILRB4/ILT3/CD85k Antibody | Anti-LILRB4/ILT3/CD85k Antibody cost | order Anti-LILRB4/ILT3/CD85k Antibody | Anti-LILRB4/ILT3/CD85k Antibody in vivo | Anti-LILRB4/ILT3/CD85k Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.